Roche Mounts NMOSD Challenge To Alexion’s Soliris

 
• By Andrew McConaghie

Satralizumab will be boosted by convenience and MS portfolio in increasingly competitive field.

Roche
• Source: Roche

More from Neurological

More from Therapy Areas